Prophylaxis of Fungal Infections in Neutropenic Patients with Hematologic Malignancies

  • F. Kroschinsky
  • U. Schuler
Conference paper


Prophylaxis against invasive fungal infection (IFI) in neutropenic patients remains a cornerstone of antifungal strategies mainly because diagnosis of fungal infections remains fraught with problems and the therapy of clinically overt infection, especially with molds, remains associated with high mortality. For most hematological diseases, the current therapeutic strategy relies on repetitive courses of chemotherapy. After an episode of IFI the risk of recurrence of the infections in a new episode of neutropenia is substantial. Therefore case-fatality rates of IFI do not reflect the entire prognostic impact of these infections, as the further therapy of the respective underlying disease may be hampered, delayed or entirely impossible. Overall mortality rates of IFI have been reported in the range of 47–64% [1]. [2]Subgroups of patients with e.g. allogeneic transplants, graft versus host disease (GVHD) and concurrent infections (CMV) my do substantially worse, with case fatality rates of 85–100% [3].


Acute Myeloid Leukemia Fungal Infection Invasive Aspergillosis Invasive Fungal Infection Graft Versus Host Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B (1997) Cytotoxic therapyinduced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol. 15:2254–2261PubMedGoogle Scholar
  2. 2.
    Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L, Kibbler C, Kcrmery V, Offner F, Cordonnier C, Jehn U, Ellis M, Collette L, Sylvester R (1998) An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect. 37:173–180PubMedCrossRefGoogle Scholar
  3. 3.
    Meyers JD (1990) Fungal infections in bone marrow transplant patients. Semin.Oncol. 17:10–13PubMedGoogle Scholar
  4. 4.
    Gotzsche PC, Johansen HK (1997) Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ. 314:1238–1244PubMedCrossRefGoogle Scholar
  5. 5.
    Kibbler CC, Manuel R, Prentice HG (1997) Prophylactic and empirical antifungal treatment in cancer complicated by neutropenia. Combining different antifungal strategies in same systematic review is inappropriate. BMJ. 315:488–489PubMedCrossRefGoogle Scholar
  6. 6.
    Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA (1984) Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann.Intern.Med 100:345–351PubMedGoogle Scholar
  7. 7.
    Sayer HG, Longton G, Bowden R, Pepe M, Storb R (1994) Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 84:1328–1332PubMedGoogle Scholar
  8. 8.
    O’Donnell MR, Schmidt GM, Tegtmeier BR, Faucett C, Fahey JL, Ito J, Nademanee A, Niland J, Parker P, Smith EP (1994) Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol. 12:827–834PubMedGoogle Scholar
  9. 9.
    Bow EJ, Loewen R, Cheang MS, Schacter B (1995) Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect.Dis. 21:361–369PubMedCrossRefGoogle Scholar
  10. 10.
    Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkali T, Koukila-Kahkola P, Ruutu T (1997) Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 19:801–808PubMedCrossRefGoogle Scholar
  11. 11.
    Sandford GR, Merz WG, Wingard JR, Charache P, Saral R (1980) The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect.Dis. 142:503–509PubMedCrossRefGoogle Scholar
  12. 12.
    Schwartz RS, Mackintosh FR, Schrier SL, Greenberg PL (1984) Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 53:411–419PubMedCrossRefGoogle Scholar
  13. 13.
    Guiot HF, Fibbe WE, van’ t Wout(1994) Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect.Dis. 18:525–532PubMedCrossRefGoogle Scholar
  14. 14.
    Martino P, Girmenia C, Micozzi A, De Bernardis F, Boccanera M, Cassone A (1994) Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. Eur.J Clin Microbiol.Infect.Dis. 13:797–804PubMedCrossRefGoogle Scholar
  15. 15.
    Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G (1993) Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob.Chemofher. 31:973–984CrossRefGoogle Scholar
  16. 16.
    Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D’Antonio D, Ricci P, Carotenuto M, Liso V, Nosari AM (1994) Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann.Intern.Med 120:913–918PubMedGoogle Scholar
  17. 17.
    Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N.Engl.J.Med. 326:845–851PubMedCrossRefGoogle Scholar
  18. 18.
    Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J.Infect.Dis. 171:1545–1552PubMedCrossRefGoogle Scholar
  19. 19.
    Schaffner A, Schaffner M (1995) Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect.Dis. 172:1035–1041PubMedCrossRefGoogle Scholar
  20. 20.
    Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Rosenfeld CS, Ho WG, Islam MZ (1993) Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial [see comments]. Ann.Intern.Med. 118:495–503PubMedGoogle Scholar
  21. 21.
    Ninane J (1994) A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Eur.J Clin Microbiol.Infect.Dis. 13:330–337PubMedCrossRefGoogle Scholar
  22. 22.
    Prentice AG, Warnock DW, Johnson SA, Taylor PC, Oliver DA (1995) Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J.Antimicrob.Chemother. 36:657–663PubMedCrossRefGoogle Scholar
  23. 23.
    Prentice AG, Warnock DW, Johnson SA, Phillips MJ, Oliver DA (1994) Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J.Antimicrob.Chemother. 34:247–252PubMedCrossRefGoogle Scholar
  24. 24.
    Michallet M, Persat F, Kranzhofer N, Levron JC, Prat C, Belhabri A, Chwetzoff E, Le Moing JP, Fiere D, Piens MA (1998) Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Bone Marrow Transplant. 21:1239–1243PubMedCrossRefGoogle Scholar
  25. 25.
    Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, Barbabietola G, Pagano L, Leoni P, Specchia G, Caiozzo A, Raimondi R, Mandelli F (1999) Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell’ Adulto. Clin.Infect.Dis. 28:250–255PubMedCrossRefGoogle Scholar
  26. 26.
    Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW (1999) A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group [In Process Citation]. Br.J.Haematol. 105:901–911PubMedCrossRefGoogle Scholar
  27. 27.
    Harousseau JL, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, De Bock R, Rovira M, Seifert WF, Joosen H, Peeters M, De Beule K (Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob-Agents Chemother. 2000.Jul.;44.(7.:1887–1893 44:1887-1893PubMedCrossRefGoogle Scholar
  28. 28.
    Chan JD (1998) Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy. 18:1304–1307PubMedGoogle Scholar
  29. 29.
    McLachlan AJ, Tett SE (1998) Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. Ther.Drug Monit. 20:390–395PubMedCrossRefGoogle Scholar
  30. 30.
    Bow EJ, Laverdiere M, Luurila H, et al (2001) Anti-fungal prophylaxis in neutropenic cancer patients ± a meta-analysis of randomised controlled trials. Blood 94 suppl 1:339a(Abstract)Google Scholar
  31. 31.
    Karp JE, Burch PA, Merz WG (1988) An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 85:203–206PubMedCrossRefGoogle Scholar
  32. 32.
    Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, Trittin A, Kern WV, Boenisch O, Bosse D, Lenz K, Ludwig WD, Hiddemann W, Siegert W, Beyer J (1999) Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 93:3654–3661PubMedGoogle Scholar
  33. 33.
    McWhinney PH, Kibbler CC, Hamon MD, Smith OP, Gandhi L, Berger LA, Walesby RK, Hoffbrand AV, Prentice HG (1993) Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years’ experience. Clin Infect.Dis. 17:397–404PubMedCrossRefGoogle Scholar
  34. 34.
    Passweg JR, Rowlings PA, Atkinson KA, Barrett AJ, Gale RP, Gratwohl A, Jacobsen N, Klein JP, Ljungman P, Russell JA, Schaefer UW, Sobocinski KA, Vossen JM, Zhang MJ, Horowitz MM (1998) Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant. 21:1231–1238PubMedCrossRefGoogle Scholar
  35. 35.
    Wald A, Leisenring W, van-Burik JA, Bowden RA (1997) Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis. 175:1459–1466PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • F. Kroschinsky
    • 1
  • U. Schuler
    • 1
  1. 1.Medizinische Klinik und Poliklinik IDresdenGermany

Personalised recommendations